Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The gene-editing tool can alter the DNA of human cells like a precise pair of scissors.
Tecartus led to durable remission in a majority of participants in a Phase II study.
KTE-X19 led to durable remission in a majority of study participants.
“Ultimately, we want to cure the many forms of cancer, but one strategy is not going to work for all, thus the need for innovation.”
New NCCN guidelines explain how to recognize and manage immunotherapy-related toxicities.
Similar to CAR-T cells, CAR-NK cells are reprogrammed with artificial receptors to recognize and attack cancer.
The first clinical trial will test a therapy designed to target a protein on cancer cells in young people with acute myeloid leukemia.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
Our spring issue is devoted to the theme of treatment.
Denise Delatorre became one of the first people in the country to receive the cutting-edge cancer treatment called CAR-T therapy.
Some helpful websites to to look up if you or one of your loved ones is living with cancer.
$3.3 million Cancer Moonshot grant to study how immunotherapy impacts patients’ ability to fight off bugs
A month after receiving the treatment, there were higher levels of CAR T cells in the blood of patients who got the new therapy.
Genetically modified natural killer cells led to remission in eight out of eleven patients with lymphoma or leukemia.
Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.